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Abstract 
Cancer cells transformation into a normal state or into a cancer cell population which is less 
tumorigenic than the initial one is a challenge that has been discussed during last decades and it is 
still far to be solved. Due to the highly heterogeneous nature of cancer cells, such transformation 
involves many genetic and epigenetic factors which are specific for each type of tumor. Different 
methods of cancer cells reprogramming have been established and can represent a possibility to 
obtain less tumorigenic or even normal cells. These methods are quite complex, thus a simple and 
efficient method of reprogramming is still required. As soon as induced pluripotent stem cells 
(iPSC) technology, which allowed to reprogram terminally differentiated cells into embryonic stem 
cells (ESC)-like, was developed, the method strongly attracted the attention of researches, 
opening new perspectives for stem cell (SC) personalized therapies and offering a powerful in vitro 
model for drug screening. This technology is also used to reprogram cancer cells, thus providing a 
modern platform to study cancer-related genes and the interaction between these genes and the 
cell environment before and after reprogramming, in order to elucidate the mechanisms of cancer 
initiation and progression. The present review summarizes recent advances on cancer cells 
reprogramming using iPSC technology and shows the progress achieved in such field. 
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Introduction 
The term pluripotency refers to the ability of a 
stem cell (SC) to differentiate into all derivatives of the 
three germ layers: endoderm, mesoderm or ectoderm. 
Such SC population should express in vitro markers of 
pluripotent cells, form cystic embryoid bodies, which 
are in vitro three-dimensional model of early embryo, 
and produce teratomas in vivo. When reintroduced 
into early embryos, pluripotent cells are able to 
contribute partially or completely to the new 
organism development and to transmit pluripotent 
cells phenotype to the next generation [1]. 
Nevertheless, SC potency varies from the pluripotent 
state such as embryonic stem (ES) cells to 
incompletely or partially potent state as adult stem 
cells (ASC). ASC may produce differentiated cells 
derived from the three germ layers, however may not 
exhibit all aforementioned characteristics of 
pluripotent SC [2][3].  
A huge effort has been done in many research 
centers around the world in order to develop, test and 
implement protocols which could be used in 
medicine. Such protocols could be therapeutically 
effective to treat or even cure many human diseases, 
such as diabetes, Parkinson and others, including 
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different injuries that are today considered incurable 
[4][5]. The growing quest for an ideal cell with a high 
differentiation potential in the target tissue has raised 
a vast number of questions and several problems that 
must be faced by scientists, such as 
immunohistocompatibility between donor and 
recipient, as well as, bioethics issues.  
In 2006, Takahashi and colleagues [6] suggested 
a manner to solve the issue of bioethics, 
immunohistocompatibility and pluripotency, using a 
protocol quite ingenious. The group reprogrammed 
somatic cells turning them similar to pluripotent 
ESC-like using retroviral vectors containing genes 
expressed during early developmental stage. These 
reprogrammed SC were called induced pluripotent 
stem cells (iPSC).  
Cancer research also acquired a new turn due to 
iPSC technology. The reprogramming of cancer cells 
is an interest approach to study cancer-related genes 
and the interaction between these genes and cell 
environment before and after reprogramming, in 
order to elucidate the mechanisms of different stages 
of cancer development. Additionally, reprogramming 
cancer cells is one of the ways for discovering novel 
cancer treatments. Cancer cells may also be reverted 
into an immature state and, therefore, be able to 
differentiate into derivatives of the three germ layers. 
Moreover, using iPSC technology is possible to 
transform cancer cells into highly immunogenic 
tumor antigen-presenting dendritic cells, which 
represent a promising approach for cancer 
immunotherapy [7][8]. While the reprogramming of 
normal somatic cells is abundantly highlighted in 
scientific literature [9][10][11][12][13], reprogramming 
of cancer cells received less attention [14][15][16]. 
After a short introduction in reprogramming 
technology of somatic cells, the present review will be 
focused on cancer cells reprogramming using iPSC 
technologies. 
iPSC Technology 
As soon as pluripotent cells were discovered, 
many scientists have addressed their studies to better 
understand the molecular mechanisms of 
pluripotency. They demonstrated that pluripotent 
cells express a unique set of transcription factors (TF), 
which do not serve only as markers, but also are 
functionally important for the pluripotency 
maintenance [17]. Takahashi and Yamanaka [6] 
proposed the use of such TF for the induction of a 
pluripotent state in somatic cells. More than 20 TF 
were tested individually or in combination by the 
group to induce pluripotency in terminally 
differentiated somatic cells and, finally, the main 
candidates were selected: octamer 4 (Oct4), SRY 
box-containing gene 2 (Sox2), Kruppel-like factor 4 
(Klf4) and the oncogene c-Myc. These factors together 
(OSKM) were named as Yamanaka´s factors and they 
were crucial for the generation of iPSC from mouse 
embryonic fibroblasts (MEF). Yamanaka´s factors 
were also introduced into adult tail-tip fibroblasts 
derived from C57/BL6-129 mice of different ages and 
they were also able to reverse these cells into a 
pluripotent state. Later, the same method of 
reprogramming was successfully tested in human 
somatic cells [9]. 
 In spite of being an innovative method, iPSC 
methodology had low efficiency of reprogramming, 
once the best efficiency reported in scientific literature 
for human fibroblasts was 0.1%, which turns the 
method laborious and time consuming [18]. Different 
groups looked for improving reprogramming 
technology and many efforts have been done aiming 
at: (1) increasing the efficiency of reprogramming; (2) 
obtaining a pluripotent SC population capable of 
differentiating into the three germ layers-derived cell 
types in vitro and in vivo and (3) eliminating the use of 
viral plasmid transfection. In order to achieve such 
purposes, different somatic cells, such as: cord blood 
[19], peripheral blood T e B lymphocytes [20][21], 
keratinocytes [22], pancreatic β cells [23], 
amnion-derived cells [24], adipose SC [25], neural SC 
[26], astrocytes [27], dental pulp SC [28] and others 
have been reprogrammed. All these cell types have 
been reported to generate iPSC but also showed 
variable reprogramming efficiencies and kinetics 
[19][28]. Besides OSKM, other key TF have been 
considered for reprogramming, such as Nanog and 
Lin-28, which also were efficient for iPSC generation 
[29]. 
Numerous studies have shown that 
reprogramming TF can be introduced in cells by using 
adenovirus or lentivirus. However, the use of 
retrovirus remains the most used method since higher 
efficiency levels were obtained. Recently, 
non-integrating reprogramming methods have been 
developed to deliver factors into the cells in a safer 
manner, than using viral methods. The most widely 
techniques used for generating integration-free 
human iPSC are: Sendai-virus (SeV), episomal (Epi) 
and mRNA [30]. Interesting that these three 
non-integrating techniques were used in parallel with 
two integrating (retro- and lentiviral vectors) methods 
to compare their reprogramming efficiencies, which 
were: mRNA = 2.7%, SeV = 0.077%, Epi = 0.013%, 
Lenti/Retro = 0.27%. All methods produced 
good-quality iPSC, however significant differences 
were registered in aneuploidy rates, reprogramming 
efficiencies, reliability and time consuming [30]. 
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Cancer and Reprogramming 
The idea of cancer cells reprogramming is not 
new and other methods, such as nuclear 
reprogramming of somatic cells by the injection of 
tumor cells – embryonic carcinoma into normal 
blastocyst [31], by in vitro hybridization of cancer cells 
with ESCs [32] and somatic cell nuclear transfer 
(SCNT) technique, which implants an enucleated 
oocyte in a donor nucleus from a cancer cell [33] were 
already used to suppress the tumorigenic phenotype 
[34]. Several cancer cell lines have already been 
reprogrammed using one of the aforementioned 
methods. It was possible to reprogram embryonic 
carcinoma cells into an almost normal state by 
transferring a tumor cell nucleus to an enucleated 
mouse oocyte, taking an advantage from the 
embryonic microenvironment. Resulting blastocysts 
showed the ability to develop, but they had the same 
tumorigenic potential as the donor cells [35]. Other 
study used SCNT technology to reprogram melanoma 
cells. In this study, ESC-like were produced and were 
able, when re-introduced into recipient early embryo, 
to complete the normal development and to produce 
healthy offspring [35]. Recent reports provided 
additional evidences that the malignant phenotype of 
cancer cells could be suppressed in embryonic niche, 
accompanied by alternative expression of miRNA and 
by epigenetic regulation, such as DNA methylation 
[36][14]. Taken together, these data confirm the 
importance of genetic changes in the tumor 
development and raise the possibility that in certain 
tumor types, epigenetic changes may play a 
predominant role. Although epigenetic changes 
contribute to tumorigenesis, it is still poorly 
understood how it occurs and also whether it is 
reversible [37]. 
The classical view of carcinogenesis mechanisms 
has considered the tissue de- differentiation during 
the malignant process [38]. The most modern version 
is based on the hypothesis that cancer stem cells (CSC) 
arise from SC of a primitive tissue or from a specific 
population of progenitor cells that can assume 
self-renewal and unlimited growth properties [39]. 
The iPSC technology is based on the reprogramming 
of somatic cells into ESC-like by ectopic expression of 
different TF. When this reprogramming occurs, 
epigenetics markers are also re-established. All of 
these premises lead to the conclusion that the iPSC 
technology can be useful for cancer cells 
reprogramming, which in some cases may lose or 
achieve a less tumorigenic state. However, these 
reprogrammed cells vary in reprogramming status at 
a large extent and, in turn, may accomplish a partial 
or a complete pluripotent state. 
Cancer Cell Lines Reprogramming Using 
iPSC Technologies 
Different cancer cell lines were used in 
reprogramming experiments [40][41]. One important 
study employed R545-melanoma cell line, which is 
trisomic for chromosomes 8 and 11 and conditionally 
express the oncogene H-Ras [42]. In H-Ras transgenic 
animals, which also carry deletion of the ink4a/Arf 
(tumor suppressor locus), RAS transgene is activated 
specifically in melanocytes after the administration of 
doxycycline, resulting in melanoma formation [42]. 
R545-melanoma cell line was a smart choice to test 
reprogramming by TF, once the same group had 
already showed reprogramming of R545-genome by 
SCNT [35]. R545-melanoma cells were infected by 
lentiviral vectors expressing Oct4, Klf4 and c-Myc 
(OKM). ESC-like were obtained after 14 days of 
reprogramming and further analysis demonstrated 
that viral gene expression was silenced following 
reprogramming. Demethylation of Oct4 and Nanog 
promoters also occurred and R545-derived iPSC were 
able to form teratomas, as well as to give rise to 
chimeras.  
Carette and co-workers [43] reprogrammed 
KBM7 cell line previously obtained from a carrier of a 
chronic myelogenous leukemia (CML). KBM7 cell line 
possesses BCR-ABL mutation and shows karyotypic 
instability in culture [44]. Retrovirus containing 
OSKM were used to infect KBM7 cells. ESC-like 
colonies appeared at day 21 after reprogramming and 
expressed the pluripotent cell markers Oct4, Nanog 
and Sox2, while the expression of hematopoietic 
markers CD43 and CD45 was lost. The expression 
levels of Nanog and Sox2 was similar to human ESC. 
After reprogramming, the percentage of methylated 
cytosine-phosphate-guanosine (CpG) sites of Oct4 
and Nanog promoter regions was significantly lower 
than in KBM7 cell line and was comparable to human 
ESC. Also, KBM7-iPSC still presented abnormal 
karyotype and maintained the expression of 
BCR-ABL oncogene. The authors tested weather the 
removal of one or more TF would be crucial for KBM7 
cells reprogramming. Interesting that removal of 
c-Myc induced cell death, while the exclusion of Oct4, 
Sox2 or Klf4 from reprogramming mixture decreased 
iPSC phenotype and colonies formation. These 
incompletely reprogrammed colonies also maintained 
the expression of CD43, typical of parental cell line. 
ESC-like colonies of KBM7-iPSC were able to 
differentiate in vitro into hematopoietic-like cells that 
were positive for CD34, CD43 and CD45 and into 
neuronal-like cells. Also, these ESC-like colonies of 
KBM7-iPSC formed teratomas in NOD-SCID mice. In 
contrast to original KBM7 cells, which are 
imatinib-sensitive (drug used to treat different types 
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of leukemia), reprogrammed cells and their 
non-hematopoietic derivatives were shown to be 
completely resistant to this drug [43]. This study 
raises interesting questions: (i) Does reprogramming 
method with removal of c-Myc may be used as a tool 
to combat CML? (ii) Does KBM7-iPSC may be used as 
an in vitro model to study imatinib-sensitivity? 
Other authors [45] used eight different 
gastrointestinal cancer cell (GCC) lines to obtain 
iPSC-like cells. Several retroviral and lentiviral 
plasmids containing OSKM were tested and the 
selected plasmid was introduced into cancer cells by 
using lipofectamine; iPSC-like colonies were formed 
at day 31 after reprogramming. Such GCC-derived 
induced pluripotent cancer cells (GCC-iPCC) 
expressed endogenous Oct3/4, Sox2, Klf4, c-Myc and 
oncogenes, such as BCL2 and KRAS, besides the 
tumor suppressor genes TP53, P16, PTEN, FHIT and 
RB1. Nanog expression increased significantly after 
reprogramming and achieved an expression level 
comparable to the pluripotent teratocarcinoma cell 
line used as positive control. Similar to KBM7-iPSC, 
these GCC-iPCC showed epigenetic modifications 
which occurred in CpG sites in the Nanog promoter, 
confirming the immature status of this gene in 
comparison to its status in parental cell line and in in 
vitro differentiated GCC-iPCC derivatives. These 
reprogrammed cells also showed the capacity to form 
embryoid-like bodies, which adhered to plastic, 
producing attached cells named by authors as PostiPC 
cells. PostiPC cells were capable to differentiate in 
vitro into derivatives of the three germ layers. 
Tumorigenic properties of PostiPC cells in 
compassion to parental GCC were tested in 
NOD/SCID mice. The results revealed the reduction 
of tumorigenesis in “spontaneously differentiated” 
PostiPC cells. However, this study did not provide 
any information about teratoma formation or 
tumorigenic potential of GCC-iPCC. Further, the 
authors used fluoropyrimidine 5-fluorouracil (5-FU) 
in parental GCC and PostiPC cells and demonstrated 
that PostiPC cells were significantly more sensitive to 
this drug when compared to the parental cell line, 
suggesting that PostiPC cells could be more sensitive 
to therapeutic agents [45]. 
Osteosarcoma cell lines (Saos-2, MG-63, G-292 
and U-2 OS) were also reprogrammed into a 
pluripotent state using OSKM retroviral transduction 
method. After reprogramming, these cells showed 
morphology resembling ESC colonies and expressed 
alkaline phosphatase, besides pluripotent markers: 
Oct4, SSEA4, TRA-1-60 and TRA-1-81. 
Reprogrammed sarcoma cells showed capacity to 
differentiate into adipocytes and osteocytes. They 
showed variable responses of reprogramming in 
respect of efficiency and long term culture effect [46].  
Different from aforementioned cell lines, human 
skin cancer cells were reprogrammed using mir-302 
microRNA (miRNA), which is expressed in 
slow-growing human ESC. The mir-302 – transfected 
cells expressed markers of ESC and showed a highly 
demethylated genome. These mirPS cells were able to 
differentiate into neuron-, chondrocyte-, fibroblast-, 
and spermatogonia-like primordial cells. The use of 
intronic mir-302 transfection represents a new and 
promise tool for the generation of pluripotent stem 
cells derived from cancerous cells [47]. 
Table 1 summarizes current knowledge which 
used iPSC technology to harvest cancer-derived 
reprogrammed cells. All features mentioned in the 
table refer to a characteristic necessary to classify a 
pluripotent cell. Considering the efficiency of 
reprogramming methods or the combination of TF 
used during the process, there is no completely 
reprogrammed population of cancer cells. 
Cancer Cell Lines Reprogramming Using 
iPSC Technologies and Hypoxia 
It is of common knowledge that hypoxia helps to 
maintain undifferentiated state of normal cells and 
CSC, as well as it also effects proliferation and cell-fate 
commitment [48][49]. In order to test the effect of 
hypoxia on cancer cells reprogramming, human lung 
adenocarcinoma A549 epithelial cell line was infected 
first by retrovirus expressing hypoxia-inducible factor 
(HIF) and next by lentivirus expressing Oct4, Sox2, 
Nanog and Lin28 (OSLN). ESC-like were collected at 
day 12 after reprogramming and the expression levels 
of endogenous Nanog and Oct4 in A549 iPS-like cells 
were lower than in normal human ESC, used as 
control. The promoter of Oct4 was only partially 
unmethylated, thus suggesting that these cells were 
not fully reprogrammed. The tumorigenic capacity of 
these partially reprogrammed A549 iPSC-like colonies 
was assessed in vivo. The colonies were injected into 
the femoral muscle of immune compromised mice 
and the cells rapidly produced highly aggressive 
tumors [50]. The results obtained by Mathieu and 
colleagues [50] suggest that hypoxia targets are crucial 
for maintaining the stemness in malignant cells. 
Hypoxia was also used for reprogramming 
HCT116 colorectal cancer cells and mutant 
TP53-deficient HCT116 cells, which showed increased 
iPCC generation efficiency. Additionally, both of 
these cells showed reduced proliferation, invasive and 
tumorigenic capacities after reprogramming. 
Transplantation of iPCC derived from TP53-deficient 
HCT116 cells into NOD/SCID mice resulted in more 
rapidly tumor formation, when compared to the same 
cells without the mutation [51] (Table 1). 
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Table 1. Studies relating cancer-derived cells reprogrammed by iPSC technology. 
CANCER CELL 
LINES 
Karyotype Reprogramming 
methods 
Viral gene 
expression 
Epigenetic 
Modification 
In vitro 
Differentiation 
capacity 
Teratomas/ 
Tumors 
formation 
Chimeras Drug 
sensitivity 
Authors 
Mice Melanoma 
R545 cell line 
Ras-induction 
Trisomy 
Chromosomes 
8 and 11 
Lentiviral OKM1 Silenced Demethylation 
Oct4 and 
Nanog 
Promoters 
Unknown Yes Yes No tumors in 
the absence of 
DOX2 
Utikal 
et al., 
2009 
Human 
Leukemia 
KBM7 CML 
Tetraployd,  
chromossomes 
9 and 22 Ph(+) 
a. Retrovirus 
OSKM3 
Unknown Partly 
demethylated 
Oct4 and 
Nanog 
Incomplete 
Neuronal- and 
hemat - like 
cells 
Yes Not 
applied 
Non-hemat. 
Derivatives 
are imatinib 
resistant – Cell 
type specific 
drug 
sensitivity 
Carette 
et al., 
2010 
b. Retrovirus 
OSK4 
Incomplete 
Reprogramming 
Unknown Unknown __ 
Human 
gastrointestinal 
cancer cells 
Abnormal Retrovirus and 
Lentivirus + 
Lipofectamine + 
OSKM 
Silenced Demethylation 
of Nanog 
promoter;               
Histone 
modification 
Derivatives of 
three germ line 
GCC5 - 
Tumor            
GCC - iPSC      
Unknown         
PotsiPC cells                
-                                
Tumor 
Not 
applied 
PotsiPC cells 
-more 
sensitive to 
5-FU6    and 
Differentiation 
Inducing 
drugs 
Miyoshi 
et al., 
2010 
Human 
gastrointestinal 
cancer cells 
Abnormal Retrovirus and 
Lentivirus + 
Lipofectamine + 
OSKM 
Long term culturing  - down regulation of endogenous OCT4, SOX2, KLF4 and c-MYC up regulation 
and high tumorigenic ability 
Nagai et 
al., 2010 
Human 
Osteosarcoma 
and 
liposarcoma 
Abnormal Lentivirus 
OSKM 
+ Nanog 
+Lin28 
Silenced Unknown Ectoderm and 
endoderm 
derivatives; 
Mesoderm 
with less 
efficiency 
Tumors less 
aggressive 
than parental 
line. 
No tumor 
after injection 
into mice of 
differentiated 
Cancer 
derived iPC7 
cells 
Not 
applied 
Unknown Zhang 
et al., 
2013 
Human lung 
adenocarcinoma 
A549 epithelial 
cell line 
Abnormal Lentivirus + 
OSLN8 + 
hypoxia 
Unknown Partly 
demethylated 
Oct4 
Unknown Highly 
aggressive 
tumors 
Not 
applied 
Unknown Mathieu 
et al., 
2011 
HCT116 
colorectal 
cancer cells 
Abnormal Lentivirus + 
OSLN + hypoxia 
Unknown Unknown Unknown Reduced 
Tumor 
Formation 
Not 
applied 
Unknown Hoshino 
et al., 
2012 
HCT116 
colorectal 
cancer cells 
+ TR53-deficient 
Abnormal Lentivirus + 
OSLN + hypoxia 
Unknown Unknown Unknown Highly 
aggressive 
tumors 
Not 
applied 
Unknown Hoshino 
et al., 
2012 Increased 
efficiency 
Solid primary 
human cancer - 
pancreatic 
ductal 
adenocarcinoma 
(PDAC) 
Aberrant 
karyotype 
~20 
chromosomal 
aberrations 
Lentiviral (dox)- 
regulated vector 
+ OSKM 
Unknown Demethylation 
Oct4 and 
Nanog 
Promoters 
Unknown Yes 
Restricted 
Mostly 
endodermal 
Not 
applied 
Unknown Kim et 
al., 2013 
Generates 
pancreatic 
intraepithelial 
neoplasia 
Abbreviations: 1Oct4, Klf4 and c-Myc; 2Doxiciclin; 3Oct4, Sox2, Klf4 and c-Myc; 4Oct4, Sox2 and c-Myc; 5Gastrointestinal cancer cell; 65-fluorouracil; 7induced pluripotent 
cancer; 8Oct4, Sox2, Lin-28 and Nanog. 
 
Reprogramming of Solid Primary Human 
Cancer 
According to current knowledge, only one study 
reported the reprogramming of solid primary human 
cancer - pancreatic ductal adenocarcinoma (PDAC) - 
using iPSC technology. Usually, PDAC is detected at 
advanced stage thus having a poor prognosis to the 
patient, with less than 5% survival rate. PDAC is 
initiated by a mutation at KRAS (proto-oncogene that 
encodes an ~21 kDa small GTPase), which is present 
in more than 90% of PDAC cases [52]. There are no in 
vitro models in scientific literature which allow study 
early stages of PDAC. Therefore, reprogramming of 
PDAC cells may be a tool for studying the progress of 
the disease. Kim and colleagues [53] obtained biopsies 
from nine patients and isolated epithelial cancer cells. 
These cells were infected with doxycycline 
(dox)-regulated lentiviral vector expressing OSKM, 
while the margin cells of the biopsies were used as 
control. Four ESC-like lines from nine tumors were 
obtained. They harbored the same KRAS G12D 
mutation observed in the initial tumor epithelial 
population, besides possesses aberrant karyotype 
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(~20 chromosomal aberrations). Reprogrammed 
cancer cells expressed pluripotent cell makers, such 
as: Oct4 and Nanog (original tumors were negative 
for such markers). Demethylation was observed in 
several sites of Nanog and Oct4 promoters of 
reprogrammed cancer cells, which showed similar 
demethylation pattern as human ESC. 
Reprogrammed cancer cells formed embryoid bodies 
in vitro and teratomas in vivo. These teratomas 
generated mostly endodermal structures in contrast to 
human ESC used as control, which produced mainly 
neuronal cell lines. Only one reprogrammed PDAC 
cell line, when injected into immunodeficient mice, 
generated pancreatic intraepithelial neoplasia 
(PanIN), precursor of PDAC. The cells isolated from 
PanIN-like structure secreted proteins that are 
expressed in human PDAC during cancer 
progression. The authors used iPSC technology and 
succeeded to generate partially reprogrammed cells 
from PDAC and also provided a human cell model of 
early pancreatic cancer [53] (Table 1).  
Reprogramming of Cancer Cells into a 
Less Tumorigenic State and Derivation of 
Potentially Malignant Cells from iPSC 
Cells reprogramming may have different 
objectives and one of them consist on the 
establishment of in vitro models to study the 
mechanisms of cancer cells transformation into a less 
tumorigenic state, as well as the transformation of 
normal cells into a malignant state. Both of these 
models, especially in combination, are of great interest 
once it may help to understand the mechanisms of 
malignant transformation and answer the question of 
how normal cells may become cancer cells. Although 
Utikal and co-authors [41] already demonstrated the 
reprogramming of melanoma cells into almost typical 
iPSC, they did not show if this state is reversible. Also, 
it was not clear whether normal iPSC in a tumor 
microenvironment will have a risk of malignant 
transformation. This is important as the main issue of 
iPSC transplantation into patients is about safety 
concerns, once these cells tend to form teratomas. 
Recently, it has been shown that mouse iPSC cultured 
in conditioned media by cancer cell lines showed 
tumorigenic capacity [54][55]. After transplantation 
into nude mice, all iPSC lines showed formation of 
malignant tumors and one iPSC line enhanced 
angiogenesis formation. This work demonstrated that 
iPSC is an interesting model for the study of 
malignant cell transformation and also alerts us about 
possible malignant transformation of normal iPSC 
and their derivatives.  
Li-Fraumeni syndrome (LFS) is a rare autosomal 
dominant disease, related to mutations at the TP53 
gene and characterized by the occurrence of multiple 
tumors in the same person. Lee and collaborators [56] 
obtained iPSC from skin fibroblasts of LFS patient 
with osteosarcoma. Mesenchymal stem cells (MSC) 
derived from these iPSC upon differentiation were 
able to differentiate into osteoblasts, which in turn, 
generated osteosarcoma after their injection into nude 
mice. This study demonstrated that malignant 
transformation depends, at least in this case, on cell 
specification, once iPSC-derived MSC were not able to 
form any type of tumor. It is still interesting to derive 
iPSC from primary tumor cells of LFS patients. The 
generation of such pairs of cell lines obtained from 
normal and malignant cells of the same patient is a 
model of interest for studying the mechanisms of 
tumor transformation, tumor progression and the 
reversion to normal or malignant state. 
Why do We Want to Reprogram Cancer 
Cells? 
The reprogramming of cancer cells have several 
basic aims: (1) to explore the possibility to normalize 
in vivo the malignant phenotype of such cells, as an 
alternative to conventional therapeutic protocols; (2) 
to yield a larger CSC population, which would be 
available for experimental manipulation and for 
exploration of their biological properties to better 
understand resistant tumors and reduce relapses; (3) 
to produce less tumorigenic iPSC derived from cancer 
cells that may be differentiated into a specific cell type 
e.g. dendritic cells or cytotoxic T cells, in order to 
prepare specific cancer vaccines; (4) to use 
cancer-derived iPSC for pharmacological screenings 
[57]; (5) to use reprogrammed cancer cells to create 
novel therapeutic targets against CSC by combining, 
for example, small non-coding RNAs with efficient 
drug delivery systems [58]; and (6) to create a 
powerful tool for distinguishing epigenetic and 
genetic alterations that occur during tumor 
development and progression [40] (Figure 1).  
Several factors can enhance the efficiency of iPSC 
generation, such as cell cycle checkpoints mediated by 
the cyclin-dependent kinase inhibitor family. The 
transient inhibition of these proteins may significantly 
improve iPSC generation [33][59], although the ability 
of the resultant cells to become non tumorigenic is not 
completely understood. During reprogramming, cells 
increase their intolerance to different types of DNA 
damage. The mechanisms which occur in cancer cells 
and then undergo an incomplete form of 
reprogramming, such as the presence of CSC that may 
increase the heterogeneity of a cancer cell population, 
remain unclear [58]. It has been proposed that two 
types of SC coexist in normal and in cancer 
microenvironment and that these cells populations 
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are transient and are regulated by epigenetic controls 
[60][61]. Emerging evidence indicates that quiescent 
and active SC subpopulations that are in lower 
metabolic and proliferative states, respectively, may 
coexist in several tissues [61]. Endogenous expression 
levels of TF during early embryogenesis and in 
pluripotent cells could be relevant for tumor cell 
malignancy and transformation [62]. 
Conclusions 
The investigation of cellular reprogramming and 
pluripotency encompasses several important decades 
in the recognition of similarity between normal 
pluripotent cells and tumor cells. Cellular 
mechanisms involved in normal pluripotent SC 
differentiation and in abnormal growth and 
differentiation of CSC in the neoplasia were also 
addressed [40][63]. 
Recent studies demonstrate that Yamanaka`s 
method [6] can be successfully used for 
reprogramming cancer cell. Similar to normal cells, 
cancer cells also showed variable reprogramming 
efficiencies and kinetics. They respond differentially 
to each reprogram method when removing or adding 
TF in the reprogramming vector. It seems that in 
contrast to normal cells, which after reprogramming 
and in vitro long-term cultivation tend to preserve 
their pluripotent properties, cancer reprogrammed 
cells demonstrate down regulation of pluripotent 
genes and up regulation of the oncogene c-Myc. 
These cells also showed epigenetic modifications 
following reprogramming. Until now, the majority of 
cancer cells used for reprogramming experiments is 
from cancer cell lines, which are already highly 
instable and frequently do not reflect the true scenario 
of cancer cells populations, when compared to the 
model of primary cells isolated from tumors. 
Therefore, the number of studies using primary 
cancer cells should be increased in order to provide 
more adequate models for drug screening.  
The small number of studies described in this 
present review already demonstrates the usefulness of 
this model for cancer studies. Herein, we show that 
although great advances on reprogramming efficiency 
of cancer cells have been made, the heterogeneity of 
such cells remains to be investigated as a novel 
therapeutic approach. The most striking conclusion is 
that cancer cells reprogramming results in the ability 
of the cancer cells to re-engage and terminally execute 
normal cellular differentiation pathways with 
consequent reduction of tumorigenic properties [42]. 
 
 
Figure 1. The reprogramming of cancer cells focuses on possible therapeutic use of iPSC-like cancer cells and at cancer remodeling. Cancer- derived iPSC lines can 
be differentiated into different cell types in order to investigate the features of cancer progression and drug screening or to develop cell-based therapies. On the other 
hand undifferentiated cancer-derived iPSC lines may be useful for further cancer research. 
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